Clinical trials: sponsored by AbbVie
Healthy Volunteers
A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Dosing in Healthy Male Participants
The objective of this study is to evaluate the bioavailability, safety and tolerability of risankizumab following subcutaneous injections in healthy male participants.
- Trial name
- NCT05283694
- Testing
- risankizumab
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
Study to Evaluate the Effect of Different Warm-Up Times of Risankizumab Autoinjector (AI) on the Injection Pain Experiences in Healthy Volunteers
The objective of this study is to assess the impact of different warm-up times of risankizumab autoinjector (AI) on the participant injection site pain experience in healthy adult volunteers.
- Trial name
- NCT05274087
- Testing
- Risankizumab
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants
The primary objectives of this study are to assess the relative bioavailability of risankizumab in on-body delivery system (OBDS) versus the prefilled syringe (PFS) (Substudy 1) and to assess the relative bioavailability of…
- Trial name
- NCT05274100
- Testing
- Risankizumab
- Where
- 8 sites in United States
- Volunteers
- 394 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China
The objective of this study to assess the pharmacokinetics, safety, tolerability and immunogenicity following a single subcutaneous (SC) or intravenous (IV) dose of risankizumab in healthy Chinese participants.
- Trial name
- NCT05268068
- Testing
- Risankizumab
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AbbVie
Atopic Dermatitis
A Non-Drug Study Detecting And Quantifying Nocturnal Scratch Behaviors From Wrist Actigraphy Data In Adult Healthy Volunteers And Participants With Atopic Dermatitis (AD)
Sleep disturbance is very common in patients with atopic dermatitis (AD) and is a major factor leading to impaired quality of life. Nocturnal scratching is one of the factors causing sleep disturbance in AD patients.
- Trial name
- NCT04262791
- Testing
- Wrist Actigraphy Device, Sleep Headband
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AbbVie
Psoriasis
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis
This is a study to evaluate pharmacokinetics (PK), safety and tolerability of ABBV-157 in healthy volunteers and in participants with chronic plaque psoriasis, and to evaluate the efficacy of ABBV-157 in the participants with…
- Trial name
- NCT03922607
- Testing
- ABBV-157
- Where
- 10 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- AbbVie
Colorectal Cancer (CRC), Gastric Cancer
A Study of SC-007 in Subjects With Advanced Cancer
This is a multicenter, open-label, Phase 1 study in participants with colorectal cancer (CRC) or gastric cancer to study the safety and tolerability of SC-007 and consists of Part A (dose regimen finding) in participants with CRC…
- Trial name
- NCT03253185
- Testing
- SC-007
- Where
- 7 sites in United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy
An Open-Label Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure to Testosterone Gel 1.62% Applied to the Upper Arms and Shoulders and Use of a T-shirt Barrier
Single-center, single dose, open-label study in healthy male and female volunteers to further characterize the transfer potential of Testosterone Gel 1.62% formulation.
- Trial name
- NCT01130298
- Testing
- Testosterone Gel 1.62%
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AbbVie
HCV Infection
Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects
The purpose of this study is to assess the safety, tolerability, pharmacokinetics of ABT-333 in healthy volunteers and the antiviral activity in HCV infected subjects.
- Trial name
- NCT00696904
- Testing
- ABT-333
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- AbbVie
Asthma
Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With Asthma
The primary purpose of this study is to determine the safety, tolerability and pharmacokinetics of ABT-308 in healthy volunteers and patients with mild to moderate controlled asthma.
- Trial name
- NCT00986037
- Testing
- ABT-308
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- AbbVie
HCV Infection
Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1
The purpose of this study is to determine the pharmacokinetic and safety profiles of an experimental HCV protease inhibitor with and without ritonavir in healthy volunteers.
- Trial name
- NCT00850044
- Testing
- ABT-450, ritonavir
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- AbbVie
Psoriasis
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis
This is a study to assess the pharmacokinetics, safety and tolerability of multiple ascending oral doses of ABBV-553 in healthy volunteers and the pharmacokinetics, safety, tolerability and efficacy of multiple ascending oral…
- Trial name
- NCT03145948
- Testing
- ABBV-553
- Where
- 4 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy
Safety, Tolerability and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male Volunteers
Safety, tolerability and pharmacokinetics of single dose of BI 655066/ABBV-066 (risankizumab) in healthy Chinese, Japanese and Caucasian male volunteers.
- Trial name
- NCT02596217
- Testing
- ABBV-066
- Where
- 2 sites in Japan, South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- AbbVie
Renal Impairment
Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function
This is an open-label, single dose study designed to assess the pharmacokinetics and safety of ABT-493 and ABT-530 in subjects with either normal renal function or impaired renal function.
- Trial name
- NCT02442258
- Testing
- ABT-493, ABT-530
- Where
- 3 sites in United States, New Zealand
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- AbbVie
Hepatic Impairment
Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function
This is an open-label, single-dose study designed to assess the pharmacokinetics and safety of ABT-493 and/or ABT-530 in subjects with impaired hepatic function and compare them to those in subjects with normal hepatic function.
- Trial name
- NCT02296905
- Testing
- ABT-493, ABT-530
- Where
- 4 sites in United States, New Zealand
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects
The purpose of this study is to assess the pharmacokinetics and safety of multiple oral doses of ABT-450/ritonavir/ABT-267 and ABT-333 when co-administered under non-fasting conditions in healthy Chinese adult participants.
- Trial name
- NCT02534870
- Testing
- ABT-450/r/ABT-267, ABT-333
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AbbVie
Absolute Bioavailability
Bioavailability of ABT-450 and ABT-267 With Ritonavir
A study to investigate the fraction of ABT-267 and ABT-450 absorbed by the body when given in combination with each other and Ritonavir(r).
- Trial name
- NCT02052362
- Testing
- ABT-450/r/ABT-267
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AbbVie
Relative Bioavailability
Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects
This open label, Phase 1 study is to investigate the relative bioavailability of ABT-333 when delivered within different sites of the gastrointestinal tract in 12 healthy subjects.
- Trial name
- NCT02052349
- Testing
- ABT-333
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AbbVie